Differentiated thyroid cancer (DTC) is a rare malignant disease, although its incidence has
increased over the last few decades. It derives from follicular thyroid cells. Generally …

Background: Radioiodine remnant ablation (RRA) has traditionally been one of the
cornerstones of differentiated thyroid cancer (DTC) treatment. The decision to use RRA in …

Context: The use of preablation diagnostic radioiodine scans for risk stratification and
radioiodine therapy planning for differentiated thyroid cancer (DTC) remains controversial …

Objective A new risk stratification system was proposed to estimate the risk of recurrence in
patients with differentiated thyroid carcinoma (DTC) using the response to initial therapy …

Background Differentiated thyroid cancer (DTC) work-up is based on (near) total-
thyroidectomy plus thyroid remnant ablation (TRA) with 131-radioiodine in many patients …

Background The identification of neck lymph node (LN) metastases represents a very
important issue in the management of patients with differentiated thyroid carcinoma (DTC) …

We aimed to evaluate the diagnostic performance of measuring the concentration of
thyroglobulin (Tg) in the washout fluid of the needle aspiration (FNA-Tg). We performed a …

Recently, higher body mass index (BMI) has been associated with aggressive pathologic
features of papillary thyroid carcinoma. The aim of this study was to clarify the relationship …

Aim The risk of differentiated thyroid cancer (DTC) recurrence is widely evaluated according
to the 2015 ATA Risk Stratification System. Topography of malignant nodules has been …

Differentiated thyroid cancer (DTC) is the most common endocrine malignancy and the fifth
most common cancer in women. DTC therapy requires a multimodal approach, including …